Variants in the ATM-CHEK2-BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma

Genes Chromosomes and Cancer

Volumn 53, Issue 6, 2014, Pages 516-523

  Wójcicka, Anna ^a,b   Czetwertyńska, Malgorzata ^a,c   Świerniak, Michal ^a,d   Dlugosińska, Joanna ^c   Maciag, Monika ^a   Czajka, Agnieszka ^a   Dymecka, Kinga ^a   Kubiak, Anna ^a   Kot, Adam ^b   Ploski, Rafal ^a   de la Chapelle, Albert ^e   Jazdzewski, Krystian ^a,b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b UNIVERSITY OF WARSAW   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; CHECKPOINT KINASE 2;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IONIZING RADIATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID CARCINOMA;

ADULT; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BRCA1 PROTEIN; CARCINOMA; CHECKPOINT KINASE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; THYROID NEOPLASMS;

EID: 84897509495     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22162     Document Type: Article

References (41)

1. Adjadj E, Schlumberger M, de Vathaire F. 2009. Germ-line DNA polymorphisms and susceptibility to differentiated thyroid cancer. Lancet Oncol 10:181-190.
2. Akulevich NM, Saenko VA, Rogounovitch TI, Drozd VM, Lushnikov EF, Ivanov VK, Mitsutake N, Kominami R, Yamashita S. 2009. Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma. Endocr Relat Cancer 16:491-503.
3. Barrett JH, Iles MM, Harland M, Taylor JC, Aitken JF, Andresen PA, Akslen LA, Armstrong BK, Avril MF, Azizi E, Bakker B, Bergman W, Bianchi-Scarra G, Bressac-de Paillerets B, Calista D, Cannon-Albright LA, Corda E, Cust AE, Debniak T, Duffy D, Dunning AM, Easton DF, Friedman E, Galan P, Ghiorzo P, Giles GG, Hansson J, Hocevar M, Hoiom V, Hopper JL, Ingvar C, Janssen B, Jenkins MA, Jonsson G, Kefford RF, Landi G, Landi MT, Lang J, Lubinski J, Mackie R, Malvehy J, Martin NG, Molven A, Montgomery GW, van Nieuwpoort FA, Novakovic S, Olsson H, Pastorino L, Puig S, Puig-Butille JA, Randerson-Moor J, Snowden H, Tuominen R, Van Belle P, van der Stoep N, Whiteman DC, Zelenika D, Han J, Fang S, Lee JE, Wei Q, Lathrop GM, Gillanders EM, Brown KM, Goldstein AM, Kanetsky PA, Mann GJ, Macgregor S, Elder DE, Amos CI, Hayward NK, Gruis NA, Demenais F, Bishop JA, Bishop DT. 2011. Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet 43:1108-1113.
4. Botstein D, Risch N. 2003. Discovering genotypes underlying human phenotypes: Past successes for mendelian disease, future approaches for complex disease. Nat Genet 33:228-237.
5. Brennan P, McKay J, Moore L, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chow WH, Rothman N, Chabrier A, Gaborieau V, Odefrey F, Southey M, Hashibe M, Hall J, Boffetta P, Peto J, Peto R, Hung RJ. 2007. Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: Case control study. Hum Mol Genet 16:1794-1801.
6. Canzian F, Amati P, Harach HR, Kraimps JL, Lesueur F, Barbier J, Levillain P, Romeo G, Bonneau D. 1998. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 63:1743-1748.
7. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymanska A, Szymanska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubinski J. 2004. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131-1135.
8. Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, Lee EY. 1999. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18:7883-7899.
9. de la Chapelle A, Jazdzewski K. 2011. MicroRNAs in thyroid cancer. J Clin Endocrinol Metab 96:3326-3336.
10. Dufault MR, Betz B, Wappenschmidt B, Hofmann W, Bandick K, Golla A, Pietschmann A, Nestle-Kramling C, Rhiem K, Huttner C, von Lindern C, Dall P, Kiechle M, Untch M, Jonat W, Meindl A, Scherneck S, Niederacher D, Schmutzler RK, Arnold N. 2004. Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer 110:320-325.
11. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, AT. 2010. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer.
12. Falck J, Lukas C, Protopopova M, Lukas J, Selivanova G, Bartek J. 2001. Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 20:5503-5510.
13. Frich L, Glattre E, Akslen LA. 2001. Familial occurrence of nonmedullary thyroid cancer: A population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. Cancer Epidemiol Biomarkers Prev 10:113-117.
14. Goggins W, Daniels GH, Tsao H. 2006. Elevation of thyroid cancer risk among cutaneous melanoma survivors. Int J Cancer 118:185-188.
15. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. 1994. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86:1600-1608.
16. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Sigurdsson A, Bergthorsson JT, He H, Blondal T, Geller F, Jakobsdottir M, Magnusdottir DN, Matthiasdottir S, Stacey SN, Skarphedinsson OB, Helgadottir H, Li W, Nagy R, Aguillo E, Faure E, Prats E, Saez B, Martinez M, Eyjolfsson GI, Bjornsdottir US, Holm H, Kristjansson K, Frigge ML, Kristvinsson H, Gulcher JR, Jonsson T, Rafnar T, Hjartarsson H, Mayordomo JI, de la Chapelle A, Hrafnkelsson J, Thorsteinsdottir U, Kong A, Stefansson K. 2009. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet 41:460-464.
17. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Masson G, He H, Jonasdottir A, Sigurdsson A, Stacey SN, Johannsdottir H, Helgadottir HT, Li W, Nagy R, Ringel MD, Kloos RT, de Visser MC, Plantinga TS, den Heijer M, Aguillo E, Panadero A, Prats E, Garcia-Castano A, De Juan A, Rivera F, Walters GB, Bjarnason H, Tryggvadottir L, Eyjolfsson GI, Bjornsdottir US, Holm H, Olafsson I, Kristjansson K, Kristvinsson H, Magnusson OT, Thorleifsson G, Gulcher JR, Kong A, Kiemeney LA, Jonsson T, Hjartarson H, Mayordomo JI, Netea-Maier RT, de la Chapelle A, Hrafnkelsson J, Thorsteinsdottir U, Rafnar T, Stefansson K. 2012. Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet 44:319-322.
18. He H, Nagy R, Liyanarachchi S, Jiao H, Li W, Suster S, Kere J, de la Chapelle A. 2009. A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Res 69:625-631.
19. Houlston RS, Peto J. 2004. The search for low-penetrance cancer susceptibility alleles. Oncogene 23:6471-6476.
20. Jazdzewski K, de la Chapelle A. 2009. Genomic sequence matters: A SNP in microRNA-146a can turn anti-apoptotic. Cell Cycle 8:1642-1643.
21. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. 2008. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA 105:7269-7274.
22. Jazdzewski K, Liyanarachchi S, Swierniak M, Pachucki J, Ringel MD, Jarzab B, de la Chapelle A. 2009. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci USA 106:1502-1505.
23. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. 2012. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab 97:E878-E887.
24. Kaufman B, Laitman Y, Gronwald J, Winqvist R, Irmejs A, Lubinski J, Pylkäs K, Gardovskis J, Miklasevics E, Friedman E. 2009. Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations. Fam Cancer 8:473-478.
25. Kilpivaara O, Vahteristo P, Falck J, Syrjakoski K, Eerola H, Easton D, Bartkova J, Lukas J, Heikkila P, Aittomaki K, Holli K, Blomqvist C, Kallioniemi OP, Bartek J, Nevanlinna H. 2004. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 111:543-547.
26. Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA, Nevanlinna H. 2006. CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet 43:e34-.
27. Kim S, Parks CG, Xu Z, Carswell G, DeRoo LA, Sandler DP, Taylor JA. 2012. Association between genetic variants in DNA and histone methylation and telomere length. PLoS ONE 7:e40504.
28. Landa I, Robledo M. 2011. Association studies in thyroid cancer susceptibility: Are we on the right track? J Mol Endocrinol 47:R43-R58.
29. Lavin MF. 2008. Ataxia-telangiectasia: From a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9:759-769.
30. Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, Goh C, Govindasami K, Guy M, O'Brien L, Sawyer E, Hall A, Wilkinson R, Easton D, Goldgar D, Eeles R, Kote-Jarai Z. 2012. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 106:1697-1701.
31. Li J, Williams BL, Haire LF, Goldberg M, Wilker E, Durocher D, Yaffe MB, Jackson SP, Smerdon SJ. 2002. Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell 9:1045-1054.
32. Liyanarachchi S, Wojcicka A, Li W, Czetwertynska M, Stachlewska E, Nagy R, Hoag K, Wen B, Ploski R, Ringel MD, Kozlowicz-Gudzinska I, Gierlikowski W, Jazdzewski K, He H, de la Chapelle A. 2013. Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma. Thyroid PMID: 23659773.
33. Machens A, Hauptmann S, Dralle H. 2006. Disparities between male and female patients with thyroid cancers: Sex difference or gender divide? Clin Endocrinol (Oxf) 65:500-505.
34. Mazzaferri EL, Jhiang SM. 1994. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428.
35. McKay JD, Lesueur F, Jonard L, Pastore A, Williamson J, Hoffman L, Burgess J, Duffield A, Papotti M, Stark M, Sobol H, Maes B, Murat A, Kaariainen H, Bertholon-Gregoire M, Zini M, Rossing MA, Toubert ME, Bonichon F, Cavarec M, Bernard AM, Boneu A, Leprat F, Haas O, Lasset C, Schlumberger M, Canzian F, Goldgar DE, Romeo G. 2001. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 69:440-446.
36. Rudd MF, Sellick GS, Webb EL, Catovsky D, Houlston RS. 2006. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. Blood 108:638-644.
37. Siegel R, Naishadham D, Jemal A. 2012. Cancer statistics, 2012. CA Cancer J Clin 62:10-29.
38. Sigurdson AJ, Hauptmann M, Alexander BH, Doody MM, Thomas CB, Struewing JP, Jones IM. 2005. DNA damage among thyroid cancer and multiple cancer cases, controls, and long-lived individuals. Mutat Res 586:173-188.
39. Swierniak M, Wojcicka A, Czetwertynska M, Stachlewska E, Maciag M, Wiechno W, Gornicka B, Bogdanska M, Koperski L, de la Chapelle A, Jazdzewski K. 2013. In-depth characterization of the microrna transcriptome in normal thyroid and papillary thyroid carcinoma. J Clin Endocrinol Metab 98:E1401-E1409.
40. Williams LH, Choong D, Johnson SA, Campbell IG. 2006. Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clin Cancer Res 12:6967-6972.
41. Xu L, Doan PC, Wei Q, Liu Y, Li G, Sturgis EM. 2012. Association of BRCA1 functional single nucleotide polymorphisms with risk of differentiated thyroid carcinoma. Thyroid 22:35-43.